Bright Minds Net Income Applicable To Common Shares Over Time
| DRUG Stock | USD 34.03 1.91 5.31% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bright Minds Performance and Bright Minds Correlation. Bright |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Bright Minds Biosciences and related stocks such as Revelation Biosciences, Zura Bio Limited, and Phio Pharmaceuticals Corp Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | 31.7 M | (3.8 M) | (2.1 M) | (2.1 M) | (2.1 M) | (1.9 M) | (1.8 M) |
| ZURA | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (46.9 M) | (35.3 M) | (35.3 M) | (40.6 M) | (42.7 M) |
| PHIO | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (12.9 M) | (10.4 M) | (11.1 M) | (12.5 M) | (7.4 M) | (8.9 M) | (8.8 M) | (13.3 M) | (13.3 M) | (13.3 M) | (15.3 M) | (16 M) |
| ZVSA | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (8.1 M) | (14.1 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| RNAZ | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (17.6 M) | (15.8 M) | (15 M) |
| PYXS | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (12.8 M) | (76 M) | (120.7 M) | (120.7 M) | (108.6 M) | (103.2 M) |
| ELEV | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (17.3 M) | (32 M) | (95.1 M) | (95.1 M) | (85.6 M) | (81.3 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (8.2 M) | (7.4 M) | (7.8 M) |
| ADTX | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (27.6 M) | (24.9 M) | (26.1 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (10.5 M) | (9.6 M) | (9.6 M) | (8.6 M) | (9.1 M) |
| UNCY | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.2 M) | (2.3 M) | (10 M) | (10 M) | (10 M) | (9 M) | (8.6 M) |
Bright Minds Biosciences and related stocks such as Revelation Biosciences, Zura Bio Limited, and Phio Pharmaceuticals Corp Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Bright Minds Biosciences | DRUG |
| Classification | Pharmaceutical Products |
| Location | British Columbia; Canada |
| Exchange | NASDAQ Exchange |
USD 34.03
Check out Bright Minds Performance and Bright Minds Correlation. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Bright Minds technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.